477 related articles for article (PubMed ID: 17149608)
1. Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial.
Dragovich T; Huberman M; Von Hoff DD; Rowinsky EK; Nadler P; Wood D; Hamilton M; Hage G; Wolf J; Patnaik A
Cancer Chemother Pharmacol; 2007 Jul; 60(2):295-303. PubMed ID: 17149608
[TBL] [Abstract][Full Text] [Related]
2. A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma.
Duffy A; Kortmansky J; Schwartz GK; Capanu M; Puleio S; Minsky B; Saltz L; Kelsen DP; O'Reilly EM
Ann Oncol; 2008 Jan; 19(1):86-91. PubMed ID: 17878176
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of gemcitabine combined with capecitabine and erlotinib in advanced pancreatic cancer: a clinical and pharmacological study.
Francois E; Bennouna J; Chamorey E; Etienne-Grimaldi MC; Renée N; Senellart H; Michel C; Follana P; Mari V; Douillard JY; Milano G
Chemotherapy; 2012; 58(5):371-80. PubMed ID: 23235319
[TBL] [Abstract][Full Text] [Related]
4. Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727).
Philip PA; Goldman B; Ramanathan RK; Lenz HJ; Lowy AM; Whitehead RP; Wakatsuki T; Iqbal S; Gaur R; Benedetti JK; Blanke CD
Cancer; 2014 Oct; 120(19):2980-5. PubMed ID: 25041791
[TBL] [Abstract][Full Text] [Related]
5. Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer.
Kulke MH; Blaszkowsky LS; Ryan DP; Clark JW; Meyerhardt JA; Zhu AX; Enzinger PC; Kwak EL; Muzikansky A; Lawrence C; Fuchs CS
J Clin Oncol; 2007 Oct; 25(30):4787-92. PubMed ID: 17947726
[TBL] [Abstract][Full Text] [Related]
6. Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer.
Starling N; Watkins D; Cunningham D; Thomas J; Webb J; Brown G; Thomas K; Oates J; Chau I
J Clin Oncol; 2009 Nov; 27(33):5499-505. PubMed ID: 19858399
[TBL] [Abstract][Full Text] [Related]
7. Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (Pantar study).
Aranda E; Manzano JL; Rivera F; Galán M; Valladares-Ayerbes M; Pericay C; Safont MJ; Mendez MJ; Irigoyen A; Arrivi A; Sastre J; Díaz-Rubio E
Ann Oncol; 2012 Jul; 23(7):1919-25. PubMed ID: 22156621
[TBL] [Abstract][Full Text] [Related]
8. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.
Moore MJ; Goldstein D; Hamm J; Figer A; Hecht JR; Gallinger S; Au HJ; Murawa P; Walde D; Wolff RA; Campos D; Lim R; Ding K; Clark G; Voskoglou-Nomikos T; Ptasynski M; Parulekar W;
J Clin Oncol; 2007 May; 25(15):1960-6. PubMed ID: 17452677
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer.
Ko AH; Venook AP; Bergsland EK; Kelley RK; Korn WM; Dito E; Schillinger B; Scott J; Hwang J; Tempero MA
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1051-7. PubMed ID: 20130876
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine plus erlotinib for advanced pancreatic cancer: a systematic review with meta-analysis.
Yang ZY; Yuan JQ; Di MY; Zheng DY; Chen JZ; Ding H; Wu XY; Huang YF; Mao C; Tang JL
PLoS One; 2013; 8(3):e57528. PubMed ID: 23472089
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer.
Renouf DJ; Tang PA; Hedley D; Chen E; Kamel-Reid S; Tsao MS; Tran-Thanh D; Gill S; Dhani N; Au HJ; Wang L; Moore MJ
Eur J Cancer; 2014 Jul; 50(11):1909-15. PubMed ID: 24857345
[TBL] [Abstract][Full Text] [Related]
12. A two-cohort phase I study of weekly oxaliplatin and gemcitabine, then oxaliplatin, gemcitabine, and erlotinib during radiotherapy for unresectable pancreatic carcinoma.
Raftery L; Tepper JE; Goldberg RM; Blackstock AW; Aklilu M; Bernard SA; Ivanova A; Davies JM; O'Neil BH
Am J Clin Oncol; 2013 Jun; 36(3):250-3. PubMed ID: 22547007
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer.
Okusaka T; Furuse J; Funakoshi A; Ioka T; Yamao K; Ohkawa S; Boku N; Komatsu Y; Nakamori S; Iguchi H; Ito T; Nakagawa K; Nakachi K
Cancer Sci; 2011 Feb; 102(2):425-31. PubMed ID: 21175992
[TBL] [Abstract][Full Text] [Related]
14. [Erlotinib plus gemcitabine combination therapy in patients with unresectable advanced pancreatic cancer - a single-institution experience].
Takeda Y; Nakahira S; Katsura Y; Kagawa Y; Okishiro M; Takeno A; Sakisaka H; Suzuki R; Taniguchi H; Egawa C; Kato T; Tamura S
Gan To Kagaku Ryoho; 2013 Nov; 40(12):1884-6. PubMed ID: 24393954
[TBL] [Abstract][Full Text] [Related]
15. Survival benefit with the combination of docetaxel, gemcitabine and erlotinib in advanced and/or metastatic pancreatic cancer patients.
Samelis GF; Ekmektzoglou K; Tsiakou A; Giannakaki S; Konstadoulakis M
Hepatogastroenterology; 2011; 58(110-111):1776-81. PubMed ID: 21940348
[TBL] [Abstract][Full Text] [Related]
16. Biweekly gemcitabine (GEM) in combination with erlotinib (ERL): an active and convenient regimen for advanced pancreatic cancer.
Ardavanis A; Kountourakis P; Karagiannis A; Doufexis D; Tzovaras AA; Rigatos G
Anticancer Res; 2009 Dec; 29(12):5211-7. PubMed ID: 20044638
[TBL] [Abstract][Full Text] [Related]
17. Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study.
Van Cutsem E; Li CP; Nowara E; Aprile G; Moore M; Federowicz I; Van Laethem JL; Hsu C; Tham CK; Stemmer SM; Lipp R; Zeaiter A; Fittipaldo A; Csutor Z; Klughammer B; Meng X; Ciuleanu T
Br J Cancer; 2014 Nov; 111(11):2067-75. PubMed ID: 25247318
[TBL] [Abstract][Full Text] [Related]
18. The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study.
Watkins DJ; Starling N; Cunningham D; Thomas J; Webb J; Brown G; Barbachano Y; Oates J; Chau I
Eur J Cancer; 2014 May; 50(8):1422-9. PubMed ID: 24613126
[TBL] [Abstract][Full Text] [Related]
19. A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance).
Halfdanarson TR; Foster NR; Kim GP; Meyers JP; Smyrk TC; McCullough AE; Ames MM; Jaffe JP; Alberts SR
Oncologist; 2019 May; 24(5):589-e160. PubMed ID: 30679315
[TBL] [Abstract][Full Text] [Related]
20. Frontline treatment with gemcitabine, oxaliplatin and erlotinib for the treatment of advanced or metastatic pancreatic cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).
Katopodis O; Souglakos J; Stathopoulos E; Christopoulou A; Kontopodis E; Kotsakis A; Kalbakis K; Kentepozidis N; Polyzos A; Hatzidaki D; Georgoulias V
Cancer Chemother Pharmacol; 2014 Aug; 74(2):333-40. PubMed ID: 24930058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
